Publications by authors named "Keiichiro Okuda"
Article Synopsis
- ! This study investigated the safety and effectiveness of combined atezolizumab and bevacizumab therapy in liver cancer (hepatocellular carcinoma) patients who are on anti-platelet or anticoagulant medications. * ! It analyzed 185 patients, comparing those on these medications (IM out) with those not on them (IM in), finding no significant differences in progression-free survival or overall survival between the two groups. * ! The conclusion indicates that the combination therapy is safe and effective for patients taking anti-platelet agents or anticoagulants, making it a viable option for this population. *
Background And Aim: The aim of this study was to develop a novel noninvasive test using an artificial intelligence/neural network system (called HCC-Scope) to diagnose early-stage hepatocellular carcinoma (HCC) on the background of nonalcoholic steatohepatitis (NASH).
Methods: In total, 175 patients with histologically proven nonalcoholic fatty liver disease and 55 patients with NASH-HCC were enrolled for training and validation studies. Of the 55 patients with NASH-HCC, 27 (49.
Article Synopsis
- Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), are increasing causes of liver-related health issues like cirrhosis and cancer, primarily due to rising cases of obesity and associated conditions.
- Current treatments exist for viral hepatitis, but effective therapies for NAFLD have yet to be developed despite a solid understanding of its underlying mechanisms.
- This review discusses the pathophysiology of NAFLD, focusing on hepatic stellate cells, and explores potential therapeutic agents, including natural products, for managing the disease.
Immune checkpoint inhibitors (ICIs) cause various immune-related adverse events (irAEs). We encountered a patient in whom nivolumab was re-administered effectively and safely treat laryngeal cancer after nivolumab-induced cholangitis. A 60-year-old man with metastatic laryngeal squamous cell carcinoma received 3rd-line treatment with nivolumab.
View Article and Find Full Text PDFArticle Synopsis
- * After comparing 109 patients who successfully eradicated HCV before treatment with 109 who did not, results showed similar progression time, but longer treatment failure time and better survival rates for those who achieved HCV eradication.
- * The findings suggest that clearing HCV prior to treatment can improve liver function and overall survival in HCV-related HCC patients, emphasizing the importance of addressing HCV in these cases.
Chronic liver injury may result in hepatic fibrosis, which can progress to cirrhosis and eventually liver failure. There are no drugs that are specifically approved for treating hepatic fibrosis. The natural product honokiol (HNK), a bioactive compound extracted from , represents a potential tool in the management of hepatic fibrosis.
View Article and Find Full Text PDFHepatocellular carcinoma (HCC) is the most common type of primary liver cancer. HCC cells consume large amounts of glutamine to survive, but can adapt to glutamine depletion in the presence of an exogenous asparagine. L-asparaginase (ASNase) converts glutamine and asparagine to glutamate and aspartate, respectively, and has been used to treat leukemia.
View Article and Find Full Text PDFArticle Synopsis
- Combination treatments using tyrosine kinase inhibitors (TKIs) and immunotherapies have been effective in managing various cancers, but their impact on HLA-I expression in hepatocellular carcinoma (HCC) is still unclear.
- Regorafenib was found to enhance HLA-I and β2-microglobulin expression in HCC cell lines, influenced by interferon γ (IFNγ) and activated the STAT1 signaling pathway, which is critical for antitumor immunity.
- Other TKIs like sorafenib, lenvatinib, and cabozantinib showed similar effects, with regorafenib being the most effective due to its strong inhibition of the MEK/ERK pathway, suggesting a
Non-alcoholic steatohepatitis (NASH) has become a serious public health problem associated with metabolic syndrome. The mechanisms by which NASH induces hepatocellular carcinoma (HCC) remain unknown. There are no approved drugs for treating NASH or preventing NASH-induced HCC.
View Article and Find Full Text PDFAim: In Japan, transcatheter arterial chemoembolization (TACE) refractoriness for hepatocellular carcinoma has been defined as an insufficient therapeutic effect after ≥2 procedures. Insufficient TACE for intrahepatic lesions is defined as the presence of > 50% viable lesions (ineffective) or an increase in their number (progressive). This study aimed to examine the possibility of earlier evaluation of TACE refractoriness.
View Article and Find Full Text PDFBackground: Hepatic fibrosis is an independent risk factor for mortality and liver-related events in patients with nonalcoholic fatty liver disease (NAFLD). PNPLA3 rs738409 has been associated with fibrosis in viral and non-viral hepatitis. TLL1 rs17047200 also has been associated with developing hepatocellular carcinoma probably via hepatic fibrogenesis.
View Article and Find Full Text PDF